12:00 AM
 | 
Nov 22, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aptosyn exisulind: Phase II/III

Data from 92 evaluable patients with rising levels of prostate specific antigen (PSA) post-prostatectomy showed a significantly lower rise in PSA for Aptosyn-treated patients...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >